Combination therapy for neuropathic pain: A review of current evidence

Yakov Vorobeychik, Vitaly Gordin, Jianren Mao, Lucy Chen

Research output: Contribution to journalReview article

68 Citations (Scopus)

Abstract

Neuropathic pain is a debilitating chronic condition that remains very difficult to treat. Recently, a number of clinical studies have compared the effectiveness of combination drug therapy with monotherapy for neuropathic pain treatment. In this article, we summarize up-to-date clinical studies of combination therapy for the treatment of both cancer-and non-cancer-related neuropathic pain. Despite a relatively small number of clinical studies on this topic, several positive indications have emerged. First, clinical studies using gabapentin (five positive trials) and pregabalin (five positive trials and one negative trial) in combination with an opioid, cyclo-oxygenase-2 inhibitor or antidepressant have shown positive responses greater than the respective monotherapies for pain related to diabetic neuropathy and postherpetic neuropathy. Second, high-concentration (8) topical capsaicin and a 5 lidocaine patch seem to be effective add-on therapies (a modality of combination therapy) for various neuropathic pain conditions. Third, combination therapy for cancer-related neuropathic pain has yielded only limited success based on a number of small-scale clinical studies.While there are benefits of using combination therapy for neuropathic pain treatment, including better pain relief and reduced adverse effects, more clinical studies are required in order to (i) make head-to-head comparisons between combination and single-drug therapies, (ii) identify symptom-specific combination therapies for distinctive clinical neuropathic pain conditions, (iii) explore combination therapies that include non-drug modalities such as physical therapy, psychological coping and biofeedback to facilitate functional restoration and (iv) develop new and objective evaluation tools for clinical outcome assessment.

Original languageEnglish (US)
Pages (from-to)1023-1034
Number of pages12
JournalCNS Drugs
Volume25
Issue number12
DOIs
StatePublished - Dec 6 2011

Fingerprint

Neuralgia
Therapeutics
Combination Drug Therapy
Pain
Cyclooxygenase Inhibitors
Diabetic Neuropathies
Capsaicin
Lidocaine
Opioid Analgesics
Antidepressive Agents
Clinical Studies
Outcome Assessment (Health Care)
Psychology

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Vorobeychik, Yakov ; Gordin, Vitaly ; Mao, Jianren ; Chen, Lucy. / Combination therapy for neuropathic pain : A review of current evidence. In: CNS Drugs. 2011 ; Vol. 25, No. 12. pp. 1023-1034.
@article{0f7c959cc1214f909fbbdefebd3dba94,
title = "Combination therapy for neuropathic pain: A review of current evidence",
abstract = "Neuropathic pain is a debilitating chronic condition that remains very difficult to treat. Recently, a number of clinical studies have compared the effectiveness of combination drug therapy with monotherapy for neuropathic pain treatment. In this article, we summarize up-to-date clinical studies of combination therapy for the treatment of both cancer-and non-cancer-related neuropathic pain. Despite a relatively small number of clinical studies on this topic, several positive indications have emerged. First, clinical studies using gabapentin (five positive trials) and pregabalin (five positive trials and one negative trial) in combination with an opioid, cyclo-oxygenase-2 inhibitor or antidepressant have shown positive responses greater than the respective monotherapies for pain related to diabetic neuropathy and postherpetic neuropathy. Second, high-concentration (8) topical capsaicin and a 5 lidocaine patch seem to be effective add-on therapies (a modality of combination therapy) for various neuropathic pain conditions. Third, combination therapy for cancer-related neuropathic pain has yielded only limited success based on a number of small-scale clinical studies.While there are benefits of using combination therapy for neuropathic pain treatment, including better pain relief and reduced adverse effects, more clinical studies are required in order to (i) make head-to-head comparisons between combination and single-drug therapies, (ii) identify symptom-specific combination therapies for distinctive clinical neuropathic pain conditions, (iii) explore combination therapies that include non-drug modalities such as physical therapy, psychological coping and biofeedback to facilitate functional restoration and (iv) develop new and objective evaluation tools for clinical outcome assessment.",
author = "Yakov Vorobeychik and Vitaly Gordin and Jianren Mao and Lucy Chen",
year = "2011",
month = "12",
day = "6",
doi = "10.2165/11596280-000000000-00000",
language = "English (US)",
volume = "25",
pages = "1023--1034",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "12",

}

Combination therapy for neuropathic pain : A review of current evidence. / Vorobeychik, Yakov; Gordin, Vitaly; Mao, Jianren; Chen, Lucy.

In: CNS Drugs, Vol. 25, No. 12, 06.12.2011, p. 1023-1034.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Combination therapy for neuropathic pain

T2 - A review of current evidence

AU - Vorobeychik, Yakov

AU - Gordin, Vitaly

AU - Mao, Jianren

AU - Chen, Lucy

PY - 2011/12/6

Y1 - 2011/12/6

N2 - Neuropathic pain is a debilitating chronic condition that remains very difficult to treat. Recently, a number of clinical studies have compared the effectiveness of combination drug therapy with monotherapy for neuropathic pain treatment. In this article, we summarize up-to-date clinical studies of combination therapy for the treatment of both cancer-and non-cancer-related neuropathic pain. Despite a relatively small number of clinical studies on this topic, several positive indications have emerged. First, clinical studies using gabapentin (five positive trials) and pregabalin (five positive trials and one negative trial) in combination with an opioid, cyclo-oxygenase-2 inhibitor or antidepressant have shown positive responses greater than the respective monotherapies for pain related to diabetic neuropathy and postherpetic neuropathy. Second, high-concentration (8) topical capsaicin and a 5 lidocaine patch seem to be effective add-on therapies (a modality of combination therapy) for various neuropathic pain conditions. Third, combination therapy for cancer-related neuropathic pain has yielded only limited success based on a number of small-scale clinical studies.While there are benefits of using combination therapy for neuropathic pain treatment, including better pain relief and reduced adverse effects, more clinical studies are required in order to (i) make head-to-head comparisons between combination and single-drug therapies, (ii) identify symptom-specific combination therapies for distinctive clinical neuropathic pain conditions, (iii) explore combination therapies that include non-drug modalities such as physical therapy, psychological coping and biofeedback to facilitate functional restoration and (iv) develop new and objective evaluation tools for clinical outcome assessment.

AB - Neuropathic pain is a debilitating chronic condition that remains very difficult to treat. Recently, a number of clinical studies have compared the effectiveness of combination drug therapy with monotherapy for neuropathic pain treatment. In this article, we summarize up-to-date clinical studies of combination therapy for the treatment of both cancer-and non-cancer-related neuropathic pain. Despite a relatively small number of clinical studies on this topic, several positive indications have emerged. First, clinical studies using gabapentin (five positive trials) and pregabalin (five positive trials and one negative trial) in combination with an opioid, cyclo-oxygenase-2 inhibitor or antidepressant have shown positive responses greater than the respective monotherapies for pain related to diabetic neuropathy and postherpetic neuropathy. Second, high-concentration (8) topical capsaicin and a 5 lidocaine patch seem to be effective add-on therapies (a modality of combination therapy) for various neuropathic pain conditions. Third, combination therapy for cancer-related neuropathic pain has yielded only limited success based on a number of small-scale clinical studies.While there are benefits of using combination therapy for neuropathic pain treatment, including better pain relief and reduced adverse effects, more clinical studies are required in order to (i) make head-to-head comparisons between combination and single-drug therapies, (ii) identify symptom-specific combination therapies for distinctive clinical neuropathic pain conditions, (iii) explore combination therapies that include non-drug modalities such as physical therapy, psychological coping and biofeedback to facilitate functional restoration and (iv) develop new and objective evaluation tools for clinical outcome assessment.

UR - http://www.scopus.com/inward/record.url?scp=82555177320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82555177320&partnerID=8YFLogxK

U2 - 10.2165/11596280-000000000-00000

DO - 10.2165/11596280-000000000-00000

M3 - Review article

C2 - 22133325

AN - SCOPUS:82555177320

VL - 25

SP - 1023

EP - 1034

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 12

ER -